BRPI0307699A2 - Tratamento de hiperplasia benigna da próstata com sarms. - Google Patents

Tratamento de hiperplasia benigna da próstata com sarms.

Info

Publication number: BRPI0307699A2
Authority: BR; Brazil
Prior art keywords: type; subject; sarm; metabolite; isomer
Prior art date: 2002-02-07

Application number

BRPI0307699-7A

Other languages

English (en)

Inventor

Mitchell S Steiner

Karen A Veverka

Duane D Miller

James T Dalton

Kiwon Chung

Wenqing Gao

Original Assignee

Gtx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-07

Filing date

2003-02-06

Publication date

2015-06-16

2003-02-06 Application filed by Gtx Inc filed Critical Gtx Inc

2015-06-16 Publication of BRPI0307699A2 publication Critical patent/BRPI0307699A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Percussion Or Vibration Massage (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Surgical Instruments (AREA)
Steroid Compounds (AREA)

BRPI0307699-7A 2002-02-07 2003-02-06 Tratamento de hiperplasia benigna da próstata com sarms. BRPI0307699A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US35430002P	2002-02-07	2002-02-07
US36299702P	2002-03-11	2002-03-11
PCT/US2003/003447 WO2003065992A2 (en)	2002-02-07	2003-02-06	Treating benign prostate hyperplasia with sarms

Publications (1)

Publication Number	Publication Date
BRPI0307699A2 true BRPI0307699A2 (pt)	2015-06-16

Family

ID=27737453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0307699-7A BRPI0307699A2 (pt)	2002-02-07	2003-02-06	Tratamento de hiperplasia benigna da próstata com sarms.

Country Status (20)

Country	Link
US (2)	US7776921B2 (pt)
EP (1)	EP1480634B1 (pt)
JP (3)	JP4677516B2 (pt)
KR (2)	KR20100112659A (pt)
CN (2)	CN101732298B (pt)
AT (1)	ATE518537T1 (pt)
AU (2)	AU2003216174C1 (pt)
BR (1)	BRPI0307699A2 (pt)
CA (2)	CA2475108A1 (pt)
CY (1)	CY1111917T1 (pt)
DK (1)	DK1480634T3 (pt)
EA (2)	EA013399B1 (pt)
GE (1)	GEP20074122B (pt)
HR (2)	HRP20040793A2 (pt)
IL (2)	IL163380A (pt)
MX (1)	MXPA04007639A (pt)
PT (1)	PT1480634E (pt)
RS (1)	RS69704A (pt)
TW (2)	TW200918043A (pt)
WO (1)	WO2003065992A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7518013B2 (en)	2000-08-24	2009-04-14	University Of Tennessee Research Foundation	Selective androgen receptor modulators
US7759520B2 (en)	1996-11-27	2010-07-20	University Of Tennessee Research Foundation	Synthesis of selective androgen receptor modulators
US7026500B2 (en) *	2000-08-24	2006-04-11	University Of Tennessee Research Foundation	Halogenated selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) *	2001-06-25	2004-12-23	Dalton James T.	Metabolites of selective androgen receptor modulators and methods of use thereof
US7855229B2 (en)	2000-08-24	2010-12-21	University Of Tennessee Research Foundation	Treating wasting disorders with selective androgen receptor modulators
US8445534B2 (en)	2000-08-24	2013-05-21	University Of Tennessee Research Foundation	Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7622503B2 (en)	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en)	2000-08-24	2010-01-12	University Of Tennessee Research Foundation	Selective androgen receptor modulators and method of use thereof
US7919647B2 (en)	2000-08-24	2011-04-05	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) *	2001-12-06	2007-07-12	Dalton James T	Selective androgen receptor modulators for treating muscle wasting
US20060276539A1 (en) *	2002-10-16	2006-12-07	Dalton James T	Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
EP1558233A2 (en) *	2002-10-16	2005-08-03	GTX, Inc.	Treating androgen decline in aging male (adam)-associated conditions with sarms
US8309603B2 (en)	2004-06-07	2012-11-13	University Of Tennessee Research Foundation	SARMs and method of use thereof
FI20030958A0 (fi)	2003-06-27	2003-06-27	Orion Corp	Uusia yhdisteitä
MXPA05013619A (es) *	2003-06-27	2006-03-10	Orion Corp	Nuevos compuestos.
EA013738B1 (ru) *	2003-10-14	2010-06-30	Юниверсити Оф Теннесси Рисерч Фаундейшн	Лечение нарушений костной ткани с использованием селективных модуляторов адрогенных рецепторов
EA009902B1 (ru)	2004-02-13	2008-04-28	УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си	Модуляторы рецепторов андрогенов
EP1737813A1 (en) *	2004-04-13	2007-01-03	Warner-Lambert Company LLC	Androgen modulators
EP1740533A1 (en)	2004-04-22	2007-01-10	Warner-Lambert Company LLC	Androgen modulators
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
EP2289872B1 (en) *	2004-06-07	2017-08-02	University of Tennessee Research Foundation	Medical uses of a selective androgen receptor modulator
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
UA87854C2 (en) *	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20110237664A1 (en) *	2004-06-07	2011-09-29	Dalton James T	Selective androgen receptor modulators for treating diabetes
PT1753417E (pt) *	2004-06-07	2012-07-05	Univ Tennessee Res Foundation	Um modulador selectivo de receptor de androgénio e as suas utilizações medicinais
JP4874965B2 (ja)	2004-07-08	2012-02-15	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	アンドロゲン調節剤
KR20070057792A (ko)	2004-07-16	2007-06-07	선에시스 파마슈티컬스 인코포레이티드	오로라 키나아제 저해물질로서 유용한 티에노피리미딘
TW200724139A (en)	2005-05-05	2007-07-01	Warner Lambert Co	Androgen modulators
WO2007123682A2 (en) *	2006-04-03	2007-11-01	Medexis S.A.	Detection of membrane androgen receptor (mar) agents
US9844528B2 (en)	2006-08-24	2017-12-19	University Of Tennessee Research Foundation	SARMs and method of use thereof
US10010521B2 (en)	2006-08-24	2018-07-03	University Of Tennessee Research Foundation	SARMs and method of use thereof
HUE029808T2 (en)	2006-08-24	2017-03-28	Univ Tennessee Res Found	Substituted acylanilide derivatives and methods for their use
US9730908B2 (en)	2006-08-24	2017-08-15	University Of Tennessee Research Foundation	SARMs and method of use thereof
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
JP2015509538A (ja) *	2012-03-07	2015-03-30	リガンド・ファーマシューティカルズ・インコーポレイテッド	１つに統合された恒常性システムとしてのステロイドホルモン経路およびコレステロール経路
CN104487114A (zh)	2012-04-06	2015-04-01	安塔雷斯药品公司	针头辅助喷射注射给予睾酮组合物
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR102122941B1 (ko)	2012-07-13	2020-06-15	지티엑스, 인코포레이티드	선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
WO2015122858A1 (en)	2014-02-15	2015-08-20	Erdal Can Alkoçlar	A composition containing synthetic components formed for suppressing ribonucleotide reductase
HUP1400294A2 (hu)	2014-06-13	2015-12-28	Skillpharm Kft	Clopidogrel új alkalmazása
MX2017004819A (es) *	2014-10-16	2018-06-12	Gtx Inc	Metodos de tratamiento de transtornos urológicos usando sarm.

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US644970A (en) *	1899-02-06	1900-03-06	Thomas Graham Donaldson	Dental flask.
US935044A (en) *	1909-01-12	1909-09-28	Lenn G Mccorry	Valve.
US935045A (en) *	1909-06-19	1909-09-28	Robert J Mckelvey	Turn-table.
GB1360001A (en)	1971-06-16	1974-07-17	Scherico Ltd	Pharmaceutical compositions comprising substituted anilides
US3875229A (en) *	1972-11-24	1975-04-01	Schering Corp	Substituted carboxanilides
JPS6044294B2 (ja)	1976-04-15	1985-10-02	帝国臓器製薬株式会社	アニリド誘導体
US4139638A (en) *	1976-09-23	1979-02-13	Schering Corporation	Methods for the treatment of hirsutism
DE2862100D1 (en) *	1977-10-12	1983-01-05	Ici Plc	Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en)	1977-12-15	1980-03-04	Imperial Chemical Industries Limited	Amide derivatives
NZ197008A (en) *	1980-05-22	1984-10-19	Ici Ltd	Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) *	1981-04-15	1982-10-22	Mitsubishi Petrochem Co Ltd	Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
DE3372965D1 (en) *	1982-07-23	1987-09-17	Ici Plc	Amide derivatives
GB8617652D0 (en) *	1986-07-18	1986-08-28	Ici Plc	Acylanilide derivatives
GB8617653D0 (en) *	1986-07-18	1986-08-28	Ici Plc	Amide derivatives
US5162504A (en) *	1988-06-03	1992-11-10	Cytogen Corporation	Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
AU1687395A (en)	1994-01-21	1995-08-08	Sepracor, Inc.	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) *	1994-03-11	1997-03-11	The Trustees Of The University Of Pennsylvania	Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) *	1995-06-16	1997-08-12	Biophysica Inc.	Androgenic directed compositions
WO1998005962A1 (en)	1996-08-02	1998-02-12	Panvera Corporation	A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6995284B2 (en)	2000-08-24	2006-02-07	The University Of Tennessee Research Foundation	Synthesis of selective androgen receptor modulators
US20090264534A1 (en) *	1996-11-27	2009-10-22	Dalton James T	Selective androgen receptor modulators
US6071957A (en)	1996-11-27	2000-06-06	The University Of Tennessee Research Corporation	Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7205437B2 (en) *	1996-11-27	2007-04-17	University Of Tennessee Research Foundation	Selective androgen receptor modulators
JPH10182457A (ja)	1996-12-25	1998-07-07	Yuichi Hashimoto	抗アンドロゲン剤
US6160011A (en) *	1997-05-30	2000-12-12	The University Of Tennessee Research Corporation	Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) *	1997-06-04	1998-12-10	The University Of Tennessee Research Corporation	Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
JPH1135558A (ja) *	1997-07-18	1999-02-09	Zeria Pharmaceut Co Ltd	３−ベンゾイルインドール誘導体及びそれらを含有する医薬
GB9919778D0 (en) *	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
IL148192A0 (en)	1999-10-14	2002-09-12	Bristol Myers Squibb Co	Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure
KR20020091047A (ko)	1999-10-19	2002-12-05	노벡스 코포레이션	카소덱스, 그의 유도체 및 중간산물의 에난티오머를비대칭 합성하는 방법
US6593492B1 (en)	1999-10-27	2003-07-15	Nobex Corporation	Resolution of intermediates in the synthesis of substantially pure bicalutamide
UA74826C2 (en) *	2000-05-17	2006-02-15	Ortho Mcneil Pharm Inc	?-carboline derivatives as phosphodiesterase inhibitors
BR0111298A (pt)	2000-06-28	2005-05-10	Bristol Myers Squibb Co	Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
GB0016877D0 (en) *	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
US6838484B2 (en)	2000-08-24	2005-01-04	University Of Tennessee Research Foundation	Formulations comprising selective androgen receptor modulators
CN1736371B (zh) *	2000-08-24	2010-05-12	田纳西大学研究公司	选择性雄激素受体调节剂及其制药用途
US20030232792A1 (en)	2000-08-24	2003-12-18	Dalton James T.	Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en)	2000-08-24	2006-02-14	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
IL154425A0 (en) *	2000-08-24	2003-09-17	Univ Tennessee Res H Corp	Selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) *	2001-12-06	2007-07-12	Dalton James T	Selective androgen receptor modulators for treating muscle wasting
JP4605557B2 (ja)	2001-12-06	2011-01-05	ユニバーシティオブテネシーリサーチファウンデーション	選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療

2003
- 2003-02-06 PT PT03737647T patent/PT1480634E/pt unknown
- 2003-02-06 RS YU69704A patent/RS69704A/sr unknown
- 2003-02-06 US US10/359,270 patent/US7776921B2/en not_active Expired - Fee Related
- 2003-02-06 DK DK03737647.2T patent/DK1480634T3/da active
- 2003-02-06 CA CA002475108A patent/CA2475108A1/en not_active Abandoned
- 2003-02-06 AT AT03737647T patent/ATE518537T1/de active
- 2003-02-06 KR KR1020107021280A patent/KR20100112659A/ko not_active Ceased
- 2003-02-06 AU AU2003216174A patent/AU2003216174C1/en not_active Ceased
- 2003-02-06 WO PCT/US2003/003447 patent/WO2003065992A2/en active Search and Examination
- 2003-02-06 EA EA200401043A patent/EA013399B1/ru not_active IP Right Cessation
- 2003-02-06 CN CN2009101619003A patent/CN101732298B/zh not_active Expired - Fee Related
- 2003-02-06 CA CA2689080A patent/CA2689080C/en not_active Expired - Fee Related
- 2003-02-06 MX MXPA04007639A patent/MXPA04007639A/es active IP Right Grant
- 2003-02-06 HR HR20040793A patent/HRP20040793A2/xx not_active Application Discontinuation
- 2003-02-06 GE GEAP8396A patent/GEP20074122B/en unknown
- 2003-02-06 EA EA200901492A patent/EA200901492A1/ru unknown
- 2003-02-06 HR HR20100067A patent/HRP20100067A2/hr not_active Application Discontinuation
- 2003-02-06 BR BRPI0307699-7A patent/BRPI0307699A2/pt not_active IP Right Cessation
- 2003-02-06 EP EP03737647A patent/EP1480634B1/en not_active Expired - Lifetime
- 2003-02-06 JP JP2003565418A patent/JP4677516B2/ja not_active Expired - Fee Related
- 2003-02-06 KR KR1020047012236A patent/KR101032661B1/ko not_active Expired - Fee Related
- 2003-02-06 CN CN038078007A patent/CN1646115B/zh not_active Expired - Fee Related
- 2003-02-07 TW TW097147185A patent/TW200918043A/zh unknown
- 2003-02-07 TW TW092102512A patent/TWI374737B/zh not_active IP Right Cessation
2004
- 2004-08-05 IL IL163380A patent/IL163380A/en not_active IP Right Cessation
2009
- 2009-03-18 AU AU2009201084A patent/AU2009201084A1/en not_active Abandoned
- 2009-12-10 IL IL202675A patent/IL202675A/en not_active IP Right Cessation
2010
- 2010-05-10 JP JP2010108498A patent/JP2010209102A/ja not_active Ceased
- 2010-06-30 US US12/826,842 patent/US8088828B2/en not_active Expired - Fee Related
2011
- 2011-10-31 CY CY20111101039T patent/CY1111917T1/el unknown
2013
- 2013-04-11 JP JP2013082815A patent/JP2013144713A/ja active Pending

Also Published As

Publication number	Publication date
CY1111917T1 (el)	2015-11-04
EP1480634A4 (en)	2008-01-16
GEP20074122B (en)	2007-06-11
ATE518537T1 (de)	2011-08-15
CN1646115B (zh)	2010-06-09
WO2003065992A3 (en)	2004-02-26
CA2475108A1 (en)	2003-08-14
AU2003216174C1 (en)	2010-01-28
CA2689080A1 (en)	2003-08-14
TW200307537A (en)	2003-12-16
EP1480634A2 (en)	2004-12-01
EA200401043A1 (ru)	2005-06-30
AU2003216174B8 (en)	2009-01-15
CA2689080C (en)	2011-07-05
PT1480634E (pt)	2011-10-12
US8088828B2 (en)	2012-01-03
US20040053897A1 (en)	2004-03-18
JP2010209102A (ja)	2010-09-24
DK1480634T3 (da)	2011-11-14
EA013399B1 (ru)	2010-04-30
US20100280107A1 (en)	2010-11-04
TWI374737B (en)	2012-10-21
AU2003216174B2 (en)	2008-12-18
CN1646115A (zh)	2005-07-27
HRP20040793A2 (en)	2006-10-31
JP2013144713A (ja)	2013-07-25
JP4677516B2 (ja)	2011-04-27
CN101732298B (zh)	2012-09-19
KR101032661B1 (ko)	2011-05-06
WO2003065992A2 (en)	2003-08-14
IL202675A (en)	2011-06-30
IL163380A (en)	2010-06-30
AU2003216174A1 (en)	2003-09-02
TW200918043A (en)	2009-05-01
EA200901492A1 (ru)	2010-08-30
EP1480634B1 (en)	2011-08-03
KR20040089606A (ko)	2004-10-21
US7776921B2 (en)	2010-08-17
MXPA04007639A (es)	2005-07-13
AU2009201084A1 (en)	2009-04-09
RS69704A (en)	2006-12-15
HK1068103A1 (en)	2005-04-22
HRP20100067A2 (hr)	2010-04-30
KR20100112659A (ko)	2010-10-19
JP2005522431A (ja)	2005-07-28
CN101732298A (zh)	2010-06-16

Publication	Publication Date	Title
BRPI0307699A2 (pt)	2015-06-16	Tratamento de hiperplasia benigna da próstata com sarms.
WO2005000213A3 (en)	2006-04-13	Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
WO2001044247A3 (en)	2002-01-03	Agents and methods for the treatment of proliferative diseases
AU2001248701A1 (en)	2001-10-03	Inhibitors of histone deacetylase
NO20014046L (no)	2001-08-20	Gabapentinderivater for forhindring og behandling av visceral smerte
MXPA04002397A (es)	2004-12-02	Inhibidores de histona deacetilasa.
NO20060398L (no)	2006-02-28	Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
ATE357272T1 (de)	2007-04-15	Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
TW200504078A (en)	2005-02-01	Therapeutically active compounds and their use
WO2004105757A3 (en)	2005-05-12	Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2004064735A3 (en)	2004-12-16	Treatment of benign prostatic hyperplasia
WO2000007576A3 (en)	2000-03-30	INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
WO2004052236A3 (en)	2004-08-26	Methods and compositions for treatment of otitis media
WO2004084943A8 (en)	2004-12-23	Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2003092606A3 (en)	2004-01-08	Cholinesterase inhibitors to prevent injuries caused by chemicals
MY118986A (en)	2005-02-28	Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
RS92304A (en)	2006-10-27	Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention
WO2005016327A3 (en)	2005-04-14	Treatment of sleep disorders with cholinesterase inhibitors
WO2022256723A3 (en)	2023-01-05	Tgf-beta inhibitors and therapeutic use thereof
WO2009047505A3 (en)	2009-07-30	Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
EP1866329A4 (en)	2008-05-21	PEPTIDES FOR TRANSGLUTAMINASE INHIBITION
NO20073610L (no)	2007-09-12	Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
EA200401100A1 (ru)	2005-04-28	1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
ATE473001T1 (de)	2010-07-15	Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
WO2001044235A3 (en)	2002-01-17	Agents and methods for the treatment of proliferative diseases

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 10A, 11A E 12A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2017-05-23	B25B	Requested transfer of rights rejected	Owner name: GTX, INC. (US)